Follow us on Twitter
twitter icon@FreshPatents


Aldosterone patents

      

This page is updated frequently with new Aldosterone-related patent applications.




 Potassium-binding agents for treating hypertension and hyperkalemia patent thumbnailPotassium-binding agents for treating hypertension and hyperkalemia
The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.


 Pyrazolopyridyl compounds as aldosterone synthase inhibitors patent thumbnailPyrazolopyridyl compounds as aldosterone synthase inhibitors
Or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

 Biomarkers of mineralocorticoid receptor activation patent thumbnailBiomarkers of mineralocorticoid receptor activation
The present invention relates to the use of neutrophil gelatinase-associated lipocalin (ngal) and/or serpina3 as biomarkers of the mineralocorticoid receptor (mr) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a mr antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the ngal gene and/or of the serpina3 gene..
Inserm (institut National De La Sante Et De La Recherche Medicale)


 Indoline compounds as aldosterone synthase inhibitors patent thumbnailIndoline compounds as aldosterone synthase inhibitors
Or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

 Method for diagnosis of primary hyperaldosteronism patent thumbnailMethod for diagnosis of primary hyperaldosteronism
The present invention relates to methods and kits for the diagnosis of primary hyperaldosteronism (pha). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the ang ii level, in particular the steady state equilibrium ang ii level, and the aldosterone level in a biological sample, such as e.g.
Attoquant Diagnostics Gmbh


 New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors patent thumbnailNew phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, a1 and n are as described herein, compositions including the compounds and methods of using the compounds.. .

 Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase patent thumbnailPhenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, a1 and n are as described herein, compositions including the compounds and methods of using the compounds.. .

 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor patent thumbnailForms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
The invention relates to a phosphate salt or a nitrate salt of 4-(r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders..

 Compositions and treatments of heart failure in non-human mammal animals patent thumbnailCompositions and treatments of heart failure in non-human mammal animals
The invention relates to new compositions comprising an aldosterone antagonist according to a particular posology for the treatment of heart failure in non-human mammal animals.. .

 Aldosterone synthase inhibitors patent thumbnailAldosterone synthase inhibitors
And pharmaceutically acceptable salts thereof, wherein r1, r2 and r3, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes..

Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone.
Zs Pharma, Inc.

Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (osas). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist.
Vivus, Inc.

Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system

The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system.
The University Of Utah Research Foundation

Triazolopyridyl compounds as aldosterone synthase inhibitors

Or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

Imidazopyridyl compounds as aldosterone synthase inhibitors

Or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

Aldosterone synthase inhibitors

And pharmaceutically acceptable salts thereof, wherein cy, r1 and r2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes..

Amido compounds and their use as pharmaceuticals

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (mr), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess..
Incyte Corporation

Indazole compounds as aldosterone synthase inhibitors

This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.
Merck Sharp & Dohme Corp.

Aldosterone synthase inhibitors

This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase.
Merck Sharp & Dohme Corp.

Mineralocorticoid receptor antagonists

As well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula i, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula i..

Biomarkers in the selection of therapy of heart failure

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of gdf-15 (growth differentiation factor 15), endostatin, mimecan, igfbp7 (igf binding protein 7), a cardiac troponin, a bnp-type peptide, uric acid, gal3 (galectin-3), osteopontin, sst2 (soluble st2), plgf, sflt-1, p1np, cystatin c, prealbumin, and transferrin in a sample from a subject suffering from heart failure.
Roche Diagnostics Operations, Inc.

Compositions and methods for treatment of renal disease

The invention relates to methods, compositions, and kits for the treatment of proteinuria and/or hypertension (e.g., proteinuria and/or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and/or epleronone)..

Indoline compounds as aldosterone synthase inhibitors

This invention relates to indo line compounds of the structural formula i, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase.
Merck Sharp & Dohme Corp.

Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population.
Mercator Medsystems, Inc.

Mineralocorticoid receptor antagonists

The present invention is directed to compounds of the formula i: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the formula i, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula i..
Merck Sharp & Dohme Corp.

Mineralocorticoid receptor antagonists

As well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula i, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula i..

Potassium-binding agents for treating hypertension and hyperkalemia

The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.

New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor

The invention relates to a phosphate salt or a nitrate salt of 4-(r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders..

Organic compounds

Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula i can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome x, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.

Mineralocorticoid receptor antagonists

Compounds of the formula (i) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the formula (i), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the formula (i) are disclosed..

Treatment of arterial wall by combination of raas inhibitor and hmg-coa reductase inhibitor

The present invention relates to a pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and at least one hmg-coa reductase inhibitor in a subtherapeutic daily dose for use in maintaining or improving the functional and morphological properties of the arterial wall in a subject having at least one cardiovascular disorder or having at least one risk factor for cardiovascular disorder.. .

Aldosterone synthase inhibitors

And pharmaceutically acceptable salts thereof, wherein r1, r2. R3, r4, r5, r6, r7, w, y, m and n are as defined herein.

Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone.

Pyrazolopyridyl compounds as aldosterone synthase inhibitors

Or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

Mineralocorticoid receptor antagonists

The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..

Mineralocorticoid receptor antagonists

The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..

Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system

The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system.

Imidazopyridyl compounds as aldosterone synthase inhibitors

This invention relates to imidazopyridyl compounds of the structural formula: i or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

Triazolopyridyl compounds as aldosterone synthase inhibitors

This invention relates to triazolopyridyl compounds of the structural formula: [formula should be inserted here] or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.

Systems and methods for local drug delivery to kidneys

Drug-delivery systems for local drug delivery to kidneys and associated systems and methods are disclosed herein. One aspect of the present technology is directed to drug-delivery systems that include a physiological sensor, an implantable medical device, and a control module configured to communicate with the physiological sensor and to control delivery of a drug in response to a physiological parameter measured by the physiological sensor.

Potassium binding polymers for treating hypertension and hyperkalemia

The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.

Aldosterone induced vascular elastin production

Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.. .

Aldosterone synthase inhibitors

This invention relates to tricyclic triazole analogues of the formula i or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase.



Aldosterone topics:
  • Aldosterone
  • Hypertension
  • Congestive Heart Failure
  • Aldosteronism
  • Angiotensin Ii
  • Modulation
  • Angiotensin
  • Chronic Kidney Disease
  • Cushing Syndrome
  • Prophylaxis
  • Primary Aldosteronism
  • Kidney Disease
  • Adventitia
  • Renal Artery
  • Infarction


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Aldosterone for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Aldosterone with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2494

    file did exist - file did put2077

    3 - 1 - 44